By Mike Ward
Editor, Europe

OXFORD - With mutations of tumor suppressor genes such as p53 accounting for a large number of cancers, it is hardly surprising that they have become a favorite target for drug developers. But while many companies are focused on p53, the diversity of mutants across different tumor types presents an obstacle for the design of future clinical trials.